BioSpectrum Asia Magazine - January 2021
BioSpectrum Asia Magazine - January 2021
Go Unlimited with Magzter GOLD
Read BioSpectrum Asia along with 8,500+ other magazines & newspapers with just one subscription View catalog
1 Month $9.99
1 Year$99.99 $49.99
$4/month
Subscribe only to BioSpectrum Asia
1 Year $10.99
Save 7%
Buy this issue $0.99
In this issue
2021 beckbones Major Investment in R & D
The life sciences industry in Asia Pacific (APAC) region entered the year 2020 with companies entering into new agreements for expansion and focusing on applied research to develop new drugs that are affordable. During 2020, the industry, which acted timely, as covered in the January 2020 issue of BioSpectrum Asia, witnessed unprecedented collaborations with the governments due to the unexpected spread of coronavirus since December 2019. COVID-19 is expected to remain a defining issue for the life sciences industry across the globe in 2021, compelling companies to invest heavily in research and development
For Feedback Email Us : communications@biospectrumasia.com
Click here to access E-magazine
Singapore Gives Nod To Pfizer-BioNtech Covid-19 Vaccine
The Health Sciences Authority (HSA) has granted an authorization under the Pandemic Special Access Route (PSAR) for the Pfizer-BioNTech COVID-19 vaccine to be used in Singapore for the prevention of COVID-19.
1 min
Taiwan initiates new measures for management of medical masks
Taiwan has initiated two new measures to reinforce the management of medical masks.
1 min
EuBiologics partners with IVI for COVID-19 vaccine development
The International Vaccine Institute (IVI) and South Korean company EuBiologics have exchanged a Memorandum of Understanding (MoU) to cooperate in the clinical development of the COVID-19 vaccine the company is currently developing.
1 min
2021 beckons MAJOR investments IN R&D
The life sciences industry in Asia Pacific (APAC) region entered the year 2020 with companies entering into new agreements for expansion and focusing on applied research to develop new drugs that are affordable. During 2020, the industry, which acted timely, as covered in the January 2020 issue of BioSpectrum Asia, witnessed unprecedented collaborations with the governments due to the unexpected spread of coronavirus since December 2019. COVID-19 is expected to remain a defining issue for the life sciences industry across the globe in 2021, compelling companies to invest heavily in research and development.
6 mins
Evaluating COVID-19 vaccines on mutant viral strains
While the viral variants and vaccine trials are contesting with each other, Norway based Coalition for Epidemic Preparedness Innovations (CEPI) has launched a first-of-its-kind collaboration to tackle emergence of new COVID-19 viral strains and evaluate their impact on vaccine candidates in development. Tracking viral mutations and diversity is essential to ensure efficacy of COVID-19 vaccine candidates on mutant virulent strains.
5 mins
“We are confident that Sputnik V will be providing long-term immunization defence against potential new coronavirus infections”
On December 14, 2020, Moscow’s National Research Center for Epidemiology and Microbiology named ‘Gamaleya Center’ and the Russian Direct Investment Fund (RDIF) announced the efficacy of over 90 per cent of the Russian Sputnik V vaccine in Phase III post-registration clinical trials. RDIF joins partners and manufacturers in ramping up the production of Sputnik V. First batch of 300,000 doses of Sputnik V vaccine has already been delivered to Argentina by RDIF on December 24, 2020. In an interview with BioSpectrum Asia Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF), Russia shared more insight on the encouraging efficacy data of the Sputnik V with Biospectrum Asia.
4 mins
“We are planning to launch a new bioprocess controller in Q1 2021”
Bioprocess engineers develop and produce a multitude of products and ingredients available today. Their applications are diverse, and the products can be found in pharmaceutical, chemical, and nutrition industries. With an integrated portfolio comprising software, instruments, consumables, and services, Eppendorf can satisfy the demands of bioprocess development through production. To find out about what major is in store at Eppendorf Bioprocess, BioSpectrum spoke to Richard Mirro, Business Manager, Bioprocess at Eppendorf, Inc., US.
4 mins
“Australia has reinforced its standing as a world-class destination for early phase clinical development”
Avance Clinical, a leading Australian Contract Research Organization (CRO) for biotech firms, and winner of the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award, has recently partnered with Europe’s leading CRO, Cromos Pharma. The collaboration will allow biotech firms to quickly start their pre-IND early phase studies in Australia, thereafter, expanding to Central/Eastern Europe to access the large patient populations for their Phase II and III studies. In an email interaction with BioSpectrum, Yvonne Lungershausen, CEO, Avance Clinical, Australia spoke about the Australian CRO market, and the impact of COVID-19 crisis.
4 mins
“We plan to launch our prevention and early detection service in India”
London headquartered Medix Global, a provider of innovative, high quality, medical management solutions, is gradually expanding its business in Asia. With its recent entry into India, the company is geared to provide access of its global healthcare services to Indian customers. It has strong credentials for providing customers with fast-tracked and personalized medical solutions, from the right diagnosis to optimized treatment pathways. BioSpectrum Asia spoke to Sigal Atzmon, Founder and CEO, Medix Global, London, UK to find out more about the company’s growth plans in Asia.
5 mins
HiMedia gets multiple nods for COVID-19 products
HiGenoMB, the molecular biology division of Indian firm HiMedia Laboratories has received the CE/IVD approval and a nod from the Indian Council of Medical Research (ICMR) for its COVID-19 range of products.
1 min
BioSpectrum Asia Magazine Description:
Publisher: MM Activ Sci-Tech Communication
Category: Business
Language: English
Frequency: Monthly
BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:
* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.
BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.
- Cancel Anytime [ No Commitments ]
- Digital Only